增持评级表明派杰证券继续认为CVS Health相对于市场上其他股票是一个有利的投资，预计其表现将优于平均市场回报。尽管目标价下调，但公司对CVS Health通过战略举措和强劲的市场地位实现盈利增长的能力持乐观态度。

周一，TD Cowen将CVS Health (NYSE:CVS)的股票目标价从73.00美元上调至80.00美元，同时维持买入评级。此次上调反映了对该公司未来的积极展望，特别是对2025年这个关键年份的看好。TD Cowen的分析师将CVS列为2025年的首选股票，虽然承认存在较高风险，但强调了潜在的可观回报。

CVS Health has notified the state of more layoffs next year, including in Connecticut. They will affect 42 employees, 12 of ...

CVS Health promoted Dr. Sreekanth Chaguturu to lead its healthcare delivery business a year after the company spent $20 ...

Shelly Bendit, senior manager for CVS corporate communications, said Tuesday that “the additional notice to the State of ...

Piper Sandler：将CVS Health的目标价从72美元下调至64美元，维持“增持”评级。 (格隆汇) ...

TD Cowen analyst Charles Rhyee raised the firm’s price target on CVS Health (CVS) to $80 from $73 and keeps a Buy rating on ...

CVS has the potential to be an underrated buy given the beaten-down price it's at today. But in order for that to be the case ...

CVS Health said on Monday it named four new members to its board of directors as part of a deal with activist investor ...

RBC Capital：将CVS Health的目标价从68美元下调至58美元，维持“跑赢大盘”评级。(格隆汇) ...

CVS Health has added four new board members, including the chief executive of a hedge fund that has been critical of the ...

CVS Health (CVS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...